13F Holdings
中文EN

HRGN Harvard Apparatus Regenerative Technology, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1563665 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY35.1%
TTM net income YoY1.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin7.5%
Operating margin-643.0%
Net margin-642.0%
FCF margin—
EBITDA margin-642.6%

Returns

ROE-621.0%
ROA-225.6%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets83.5%
Debt / equity0.00x
Current ratio0.87x
Interest coverage-269.00x

Cash quality & payout

Operating cash flow / net income0.43x
Accruals ratio-127.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$704,000$430,000$103,000—$0
Cost of revenue$646,000$270,000$24,000——
Gross profit$58,000$160,000$79,000——
R&D expense$2.65M$2.31M$3.06M$1.74M$1.59M
SG&A expense$4.25M$5.02M$5.71M$4.41M$7.04M
Operating income-$6.92M-$7.73M-$8.99M-$6.15M-$8.64M
Interest expense$8,000$38,000$14,000$9,000—
Pretax income-$6.87M-$7.73M———
Income tax$0$0———
Net income-$6.87M-$7.73M-$8.95M-$6.07M-$7.98M
EBITDA-$6.91M-$7.71M-$8.96M-$6.10M-$8.53M
EPS (basic)-0.42-0.52-0.67-0.55-0.79
EPS (diluted)——-0.67-0.55-0.79
Weighted avg. shares (diluted)——13.46M11.35M10.06M
Balance sheet
Cash & equivalents$1.35M$2.49M$432,000$1.24M$1.29M
Short-term investments——$1.20M——
Receivables$16,000$231,000$4,000——
Inventory$16,000$80,000$50,000——
Current assets$1.83M$3.23M$783,000$1.59M$1.59M
PP&E, net$6,000$11,000$25,000$49,000$110,000
Total assets$2.68M$4.44M$2.61M$2.40M$1.87M
Current liabilities$1.53M$1.02M$968,000$1.36M$4.84M
Total liabilities$1.62M$1.22M$968,000$1.41M$4.89M
Shareholders' equity$1.06M$3.22M$1.65M-$3.19M-$3.03M
Shares outstanding17.58M15.92M13.95M12.17M10.76M
Cash flow statement
Operating cash flow-$3.83M-$4.85M-$6.94M-$5.11M-$2.63M
Capital expenditure—$0$11,000$5,000$0
Free cash flow—-$4.85M-$6.95M-$5.11M-$2.63M
Investing cash flow—$0-$11,000-$5,000$0
Financing cash flow$2.70M$6.91M$6.14M$5.06M$2.84M
Depreciation & amortization$5,000$14,000$35,000$52,000$107,000
Stock-based compensation$2.01M$2.40M$3.46M$1.03M$980,000
Share buybacks————$0

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.